Literature DB >> 9315805

The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension.

H Frank1, J Mlczoch, K Huber, E Schuster, H P Gurtner, M Kneussl.   

Abstract

In a retrospective study, we tested the hypothesis that anticoagulant therapy with warfarin sodium (Coumadin) has a beneficial influence on the long-term prognosis in patients with primary pulmonary hypertension (PPH) and aminorex-induced plexogenic pulmonary hypertension. The study included a total of 173 patients from two European cities. One hundred four of these patients took the anorectic drug aminorex (Menocil), which was available in some European countries almost 30 years ago; 69 patients had pulmonary hypertension of unexplained etiology, ie, PPH. Fifty-six of the 104 aminorex-treated patients and 24 patients in the PPH group received warfarin after diagnosis was established. For analysis, patients were divided into four groups according to their history of aminorex intake and anticoagulant therapy. Survival time, changes in hemodynamics (pulmonary arterial pressure), and improvement in quality of life (scored by the New York Heart Association [NYHA] classification) were compared and analyzed. We found that aminorex-treated patients had a better long-term prognosis than those with PPH (7.5 vs 3.9 years; p < or = 0.001). The best mean survival time of 8.3 years was found in anticoagulated aminorex-treated patients, compared to 6.1 years in nonanticoagulated aminorex-treated patients. Moreover, aminorex-treated patients who received anticoagulant therapy soon after the onset of symptoms showed significantly better prognosis (10.9 years) than those who commenced treatment 2 years thereafter (5.9 years) (p < or = 0.05). In patients with PPH, systolic pulmonary pressure was shown to influence survival time significantly (p < or = 0.0005); however, this correlation was not found in aminorex-treated patients. An improvement of symptoms like dyspnea on exertion was seen in 44.8% of the anticoagulated aminorex-treated patients, while deterioration was evident in 72.2% of the nonanticoagulated aminorex-treated patients. In conclusion, our study has shown that anticoagulant therapy had a positive influence on long-term survival and a significant improvement in quality of life in patients with PPH, in particular in patients with a history of anorectic drug intake.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9315805     DOI: 10.1378/chest.112.3.714

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  44 in total

1.  Cor Pulmonale.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

Review 2.  Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.

Authors:  Jennifer L Snow; Steven M Kawut
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

Review 3.  Pulmonary hypertension in women.

Authors:  Meredith E Pugh; Anna R Hemnes
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-11

Review 4.  Pulmonary arterial hypertension: a comparison between children and adults.

Authors:  R J Barst; S I Ertel; M Beghetti; D D Ivy
Journal:  Eur Respir J       Date:  2011-03       Impact factor: 16.671

5.  Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.

Authors:  Roberto F Machado; Mark T Gladwin
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

Review 6.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

7.  Treating pulmonary arterial hypertension: current treatments and future prospects.

Authors:  Shahzad G Raja; Shahbaz M Raja
Journal:  Ther Adv Chronic Dis       Date:  2011-11       Impact factor: 5.091

8.  Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?

Authors:  Muhammad Shahzeb Khan; Muhammad Shariq Usman; Tariq Jamal Siddiqi; Safi U Khan; M Hassan Murad; Farouk Mookadam; Vincent M Figueredo; Richard A Krasuski; Raymond L Benza; Jonathan D Rich
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-09

Review 9.  Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.

Authors:  Christopher J Ryerson; Shalini Nayar; John R Swiston; Don D Sin
Journal:  Respir Res       Date:  2010-01-29

Review 10.  Pulmonary vascular complications of liver disease.

Authors:  Jason S Fritz; Michael B Fallon; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.